A	C177536	GDC Property Terminology	C139284	Percent of Nucleotide Markers Exhibiting Instability	The relative measurement (percentage) of nucleotide repeat markers exhibiting instability to all nucleotide repeat markers tested in a biological specimen.	msi_score	msi score	
A	C177536	GDC Property Terminology	C139577	Stage R	A general term that refers to the histopathological staging of residual tumors after treatment.	residual_tumor	residual tumor	
A	C177536	GDC Property Terminology	C157135	Greatest Dimension Tumor	A measurement of the widest portion of a tumor.	greatest_tumor_dimension || tumor_largest_dimension_diameter	greatest tumor dimension || tumor largest dimension diameter	
A	C177536	GDC Property Terminology	C157437	Eye Color	The color of the iris of the eye.	eye_color	eye color	
D	C177536	GDC Property Terminology	C158775	Pathologic Depth	The longest front to back measurement of a tumor from the pathology examination of a specimen.	greatest_tumor_dimension || tumor_largest_dimension_diameter	greatest tumor dimension || tumor largest dimension diameter	
A	C177536	GDC Property Terminology	C160763	Other Molecular Analysis	A response of a type of molecular analysis other than what is included on the form.	specialized_molecular_test	specialized molecular test	
A	C177536	GDC Property Terminology	C164667	Sequence Read Count	The number of sequencing reaction results that were pooled to assemble a sequence for a genomic region of interest.	total_reads	total reads	
A	C177536	GDC Property Terminology	C172602	Primary Tumor Site Indicator	An indication as to whether an anatomical location is the primary tumor site of disease.	diagnosis_is_primary_disease	diagnosis is primary disease	
C	C177536	GDC Property Terminology	C177582	Single Cell Library Construction Kit Identifier	A unique identifier for a kit used to construct a single cell genome library. This may include the vendor name, kit name and kit version.	single_cell_library	single cell library	
A	C177536	GDC Property Terminology	C181699	Age in Days at Diagnosis	Age at the time of diagnosis expressed in days.	age_at_diagnosis	age at diagnosis	
A	C177536	GDC Property Terminology	C181702	Age in Years at Index Date	Age at the in years at the index date.	age_at_index	age at index	
A	C177536	GDC Property Terminology	C181704	Age in Years of Patient Relative at Cancer Diagnosis	The age in years at which the relative of a subject was first diagnosed with cancer.	relationship_age_at_diagnosis	relationship age at diagnosis	
A	C177536	GDC Property Terminology	C181705	ASCII Encoding Version for Read Group QC	The version of ASCII used to encode the read group quality control data.	encoding		
A	C177536	GDC Property Terminology	C181706	Assay Color Channel Name	The name of the color channel used in the measurement of probe intensity values in an assay.	channel		
A	C177536	GDC Property Terminology	C181707	Assay Plate Identifier	The identifier assigned to a plate used in an assay.	plate_name	plate name	
A	C177536	GDC Property Terminology	C181708	Assay Plate Well Identifier	The identifier assigned to a single well where a specific sample is located in a plate used in an assay.	plate_well	plate well	
A	C177536	GDC Property Terminology	C181709	Average Number of Alcoholic Drinks per Day	A question regarding the average number of alcoholic beverages a subject consumes per day.	alcohol_drinks_per_day	alcohol drinks per day	
A	C177536	GDC Property Terminology	C181710	Average Number of Alcoholic Drinks per Day per Week	A question regarding the average number of days per week that a subject consumes an alcoholic beverage.	alcohol_drinks_per_week	alcohol drinks per week	
A	C177536	GDC Property Terminology	C181711	Average Number of Times per Day Subject Uses Tobacco	A question regarding the average number of times per day that a subject uses a tobacco product.	tobacco_use_per_day	tobacco use per day	
A	C177536	GDC Property Terminology	C181712	Average Read Length	The average length for nucleic acid sequencing reads.	average_read_length	average read length	
A	C177536	GDC Property Terminology	C181713	Average Sequence Insert Size	The average insert size found during nucleic acid sequencing.	average_insert_size	average insert size	
A	C177536	GDC Property Terminology	C181715	Biospecimen Core Resource Identifier	The alphanumeric identifier assigned to a biospecimen core resource facility associated with a biospecimen.	bcr_id	bcr_id	
A	C177536	GDC Property Terminology	C181716	Biospecimen Volume	The amount of three dimensional space occupied by biological specimen.	biospecimen_volume	biospecimen volume	
A	C177536	GDC Property Terminology	C181717	Blood Test Range Lower Limit of Normal	The numerical value used as the lower limit of the normal range for a blood test for a healthy subject.	blood_test_normal_range_lower	blood test normal range lower	
A	C177536	GDC Property Terminology	C181718	Blood Test Range Upper Limit of Normal	The numerical value used as the upper limit of the normal range for a blood test for a healthy subject.	blood_test_normal_range_upper	blood test normal range upper	
A	C177536	GDC Property Terminology	C181719	CD4 Expressing Cell Nadir	The determination of the lowest amount of CD4 expressing cells in a sample or series of samples.	nadir_cd4_count	nadir cd4 count	
A	C177536	GDC Property Terminology	C181720	Consistent Pathology Review Indicator	An indicator that specifies that the findings recorded for an additional pathology review of a tissue sample are consistent with that of a prior review.	consistent_pathology_review	consistent pathology review	
A	C177536	GDC Property Terminology	C181721	Age at Undescended Testis Correction	The age of the subject when undescended testis was corrected.	undescended_testis_corrected_age	undescended testis corrected age	
A	C177536	GDC Property Terminology	C181722	Cross-Contaminated Read Fraction	The fraction of sequencing reads that have been cross-contaminated by other samples.	contamination		
A	C177536	GDC Property Terminology	C181723	Corrected Undescended Testis Laterality	The side of the body where the procedure to correct an undescended testis was performed.	undescended_testis_corrected_laterality	undescended testis corrected laterality	
A	C177536	GDC Property Terminology	C181724	Current Biospecimen Weight	The current weight of a biospecimen.	current_weight	current weight	
A	C177536	GDC Property Terminology	C181725	Data Analysis Workflow Name	The name of the workflow to process and/or analyze a data set.	workflow_type	workflow type	
A	C177536	GDC Property Terminology	C181726	Elapsed Time Between Clamping and Freezing	The time between clamping and freezing of a biospecimen.	time_between_clamping_and_freezing	time between clamping and freezing	
A	C177536	GDC Property Terminology	C181727	Elapsed Time Between Excision and Freezing	The time between excision and freezing of a biospecimen.	time_between_excision_and_freezing	time between excision and freezing	
A	C177536	GDC Property Terminology	C181728	Estimated Read Error due to Contamination	A statistical estimation of the error for a sample in nucleotide sequencing read caused by cross-sample contamination.	contamination_error	contamination error	
A	C177536	GDC Property Terminology	C181729	Experiment Name	The name assigned to an experiment.	experiment_name	experiment name	
A	C177536	GDC Property Terminology	C181730	FASTQ File Name	The name assigned to an electronic file containing FASTQ data.	fastq_name	fastq name	
A	C177536	GDC Property Terminology	C181731	FIGO Staging Edition Year	The four digit year associated with the Federation of Gynecology and Obstetrics (FIGO) edition used to stage a tumor.	figo_staging_edition_year	figo staging edition year	
A	C177536	GDC Property Terminology	C181732	Freezing Method Name	The name of the freezing method used to preserve a sample.	freezing_method	freezing method	
A	C177536	GDC Property Terminology	C181734	Gross Tumor Weight	The total weight of a tumor-bearing specimen.	gross_tumor_weight	gross tumor weight	
A	C177536	GDC Property Terminology	C181735	HCMI Catalog Reference Number	The reference number used in the Human Cancer Models Initiative (HCMI) catalog.	catalog_reference	catalog reference	
A	C177536	GDC Property Terminology	C181736	Image Acquisition Date	The date that imaging data was acquired for a sample.	imaging_date	imaging date	
A	C177536	GDC Property Terminology	C181737	Imaging Magnification	The amount or degree of visual enlargement used during image acquisition.	magnification		
A	C177536	GDC Property Terminology	C181738	Initial Biospecimen Weight	The initial weight of a biospecimen.	initial_weight	initial weight	
A	C177536	GDC Property Terminology	C181739	Legacy Project Archive Indicator	An indication specifying that a project is located in the legacy archive.	is_legacy	is legacy	
A	C177536	GDC Property Terminology	C181841	Multiplex Sequencing Sample Barcode	The barcode assigned to a nucleotide sample subjected to multiplex sequencing.	multiplex_barcode	multiplex barcode	
A	C177536	GDC Property Terminology	C181843	Sequencing Flow Cell Barcode	The barcode assigned to a flow cell used in nucleotide sequencing.	flow_cell_barcode	flow cell barcode	
A	C177536	GDC Property Terminology	C181844	Proportion Covered at Read Depth of 30X	A measurement of the proportion of a sample sequenced at a read depth of 30X.	proportion_coverage_30x	proportion coverage 30x	
A	C177536	GDC Property Terminology	C181845	Proportion Covered at Read Depth of 10X	A measurement of the proportion of a sample sequenced at a read depth of 10X.	proportion_coverage_10x	proportion coverage 10x	
A	C177536	GDC Property Terminology	C181846	Proportion Targets with No Coverage	The proportion of targeted sequences in a sample that did not reach 1x read depth.	proportion_targets_no_coverage	proportion targets no coverage	
A	C177536	GDC Property Terminology	C181847	Percent Follicular Component	A quantitative measurement of the area of follicular structures found in a sample reported as a percentage of the total area.	percent_follicular_component	percent follicular component	
A	C177536	GDC Property Terminology	C181848	Percent G/C	The percent of a nucleotide sequence comprised of guanine and cytosine.	percent_gc_content	percent gc content	
A	C177536	GDC Property Terminology	C181849	Percent Gleason Patterns 4 and 5	The percent of Gleason patterns 4 and 5 found in a sample.	gleason_patterns_percent	gleason patterns percent	
A	C177536	GDC Property Terminology	C181850	Percent Prostatic Involvement	The percent of prostatic chips derived from a single tissue sample that demonstrate neoplastic involvement.	prostatic_involvement_percent	prostatic involvement percent	
A	C177536	GDC Property Terminology	C181851	Percent Rhabdoid Features	A quantitative measurement of the area of rhabdoid features found in a sample reported as a percentage of the total area.	percent_rhabdoid_features || rhabdoid_percent	percent rhabdoid features || rhabdoid percent	
A	C177536	GDC Property Terminology	C181853	Percent Sarcomatoid Features	A quantitative measurement of the area of sarcomatoid features found in a sample reported as a percentage of the total area.	percent_sarcomatoid_features || sarcomatoid_percent	percent sarcomatoid features || sarcomatoid percent	
A	C177536	GDC Property Terminology	C181854	Tumor Ploidy	The number of sets of chromosomes in a tumor-derived sample.	tumor_ploidy	tumor ploidy	
A	C177536	GDC Property Terminology	C181855	Total Number of Nucleotide Sequences Processed	The total number of nucleotide sequences processed.	total_sequences	total sequences	
A	C177536	GDC Property Terminology	C181946	Microassay Chip Identifier	The identifier for a microassay chip.	chip_id	chip id	
A	C177536	GDC Property Terminology	C181948	Microassay Chip Position Identifier	The identifier for a specific position on a microassay chip.	chip_position	chip position	
A	C177536	GDC Property Terminology	C181949	Nucleotide Base Caller Name	The name of the software used to call the nucleotide bases in a sequencing assay.	base_caller_name	base caller name	
A	C177536	GDC Property Terminology	C181950	Nucleotide Base Caller Version	The version of the software used to call the nucleotide bases in a sequencing assay.	base_caller_version	base caller version	
C	C177536	GDC Property Terminology	C18849	Individual Cancer History	A record of a patient's medical background regarding the occurrence of cancer and cancer-related problems.	history_of_tumor || prior_malignancy	history of tumor || prior malignancy	
A	C177536	GDC Property Terminology	C38114	Route of Administration	Designation of the part of the body through which or into which, or the way in which, the medicinal product is intended to be introduced. In some cases a medicinal product can be intended for more than one route and/or method of administration.	route_of_administration	route of administration	
A	C177537	GDC Value Terminology	C111017	Amber	A yellowish-orange color.	Amber | eye_color	C157437	eye_color
A	C177537	GDC Value Terminology	C111018	Hazel	A color that consists of brown-gold and green.	Hazel | eye_color	C157437	eye_color
C	C177537	GDC Value Terminology	C116722	Gilteritinib	An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.	Gilteritinib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C121541	LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine OST31-164	A cancer vaccine containing a live, highly attenuated strain of the Gram-positive bacterium Listeria monocytogenes (LmddA) encoding a fusion protein composed of a chimeric peptide comprised of three highly immunogenic epitopes of the human tumor-associated antigen (TAA) HER2/neu (chHER2) fused to a non-hemolytic fragment of the immunostimulant listeriolysin O (LLO) protein, with potential immunostimulatory and antineoplastic activities. Upon administration of the LmddA-LLO-chHER2 vaccine OST31-164, the LmddA is taken up by phagocytic cells; then the listeriolysin portion of the expressed LLO-chHER2 can form pores in the phagolysosomes and the fusion protein can escape into the cytosol. In turn, the LLO-chHER2 is processed and presented to the immune system by major histocompatibility complex (MHC) I on the phagocytic cells. Antigen presentation activates the immune system to exert an immune response involving the recruitment and activation of T-lymphocytes against HER2-expressing tumor cells, and inhibits tumor-infiltrating T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs). This eventually results in tumor cell lysis. HER2/neu, a tyrosine kinase receptor belonging to the epidermal growth factor receptor (EGFR) family, is overexpressed in various tumor cell types.	LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C121647	Bezuclastinib	An orally bioavailable protein tyrosine kinase inhibitor of mutated forms of the tumor-associated antigen mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, bezuclastinib binds to and inhibits specific c-Kit mutants. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these c-Kit mutations. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.	c-Kit Inhibitor PLX9486 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C124133	Tamrintamab Pamozirine	An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against dipeptidase 3 (DPEP3) conjugated, via a plasma-stable valine-alanine dipeptide linker, to a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of tamrintamab pamozirine targets DPEP3 expressed on tumor cells. Upon binding and internalization, the cytotoxic, DNA cross-linking PBD moiety is released. This inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DPEP3-expressing tumor cells. DPEP3, a membrane-bound glycoprotein, is overexpressed in some ovarian cancers.	Antibody-drug Conjugate SC-003 | therapeutic_agents || Tamrintamab Pamozirine | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C124134	Samrotamab Vedotin	An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against leucine-rich repeat containing 15 (LRRC15) linked, via the protease-cleavable valine-citrulline linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of samrotamab vedotin, the samrotamab moiety targets and binds to LRRC15 expressed on cancer-associated fibroblasts (CAFs) and tumor cells. Upon binding and internalization, MMAE is released after proteolytic cleavage. MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in LRRC15-expressing CAFs and tumor cells. LRRC15, a type I membrane protein and a member of the LRR superfamily, is highly expressed on CAFs in the tumor microenvironment (TME) within some tumor stroma and on tumor cells in certain tumors.	Antibody-drug Conjugate ABBV-085 | therapeutic_agents || Samrotamab Vedotin | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C125194	Topical Fluorouracil	A topical formulation containing the antimetabolite 5-fluorouracil (5-FU), with antineoplastic activity. Upon topical administration, 5-FU is converted into the active metabolite 5-fluoroxyuridine monophosphate (F-UMP), which competes with uracil during RNA synthesis and inhibits RNA processing. Conversion of 5-FU into another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase; this results in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in DNA synthesis, and thus inhibits DNA synthesis. Altogether, this prevents the proliferation of tumor cells locally.	Topical Fluorouracil | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C126752	Mobocertinib	An orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly binds to and inhibits exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in tumor cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4. EGFR, HER-2 and -4 are receptor tyrosine kinases often mutated in numerous tumor cell types. They play key roles in tumor cell proliferation and tumor vascularization.	EGFR/HER2 Inhibitor AP32788 | therapeutic_agents || Mobocertinib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C128266	PTEF-b/CDK9 Inhibitor VIP152	An inhibitor of cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF- b; PTEFb), with potential antineoplastic activity. Upon administration, VIP152 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of gene transcription of various anti-apoptotic proteins. This may cause cell cycle arrest and induce apoptosis, which may lead to a reduction in tumor cell proliferation. The protein complex PTEF-b, a heterodimer consisting of CDK9 and a regulatory cyclin subunit of the T family, is over-activated in various tumor cell types; it plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.	PTEF-b/CDK9 Inhibitor BAY1251152 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C13332	Bilateral	Affecting both sides of the body or a matched pair of organs.	Bilateral | biospecimen_laterality || Bilateral | laterality || Bilateral | undescended_testis_corrected_laterality	C177605 || C181723 || C25185	biospecimen_laterality || undescended_testis_corrected_laterality || laterality
C	C177537	GDC Value Terminology	C139578	Stage R0	No detectable presence of residual tumor after treatment	R0 | residual_disease || Stage R0 | residual_tumor	C139577 || C4809	residual_tumor || residual_disease
C	C177537	GDC Value Terminology	C139580	Stage R2	Presence of macroscopic residual tumor after treatment.	R2 | residual_disease || Stage R2 | residual_tumor	C139577 || C4809	residual_tumor || residual_disease
C	C177537	GDC Value Terminology	C139581	Stage RX	Presence of residual tumor after treatment cannot be assessed.	RX | residual_disease || Stage RX | residual_tumor	C139577 || C4809	residual_tumor || residual_disease
A	C177537	GDC Value Terminology	C139980	Stage IIIA1	A stage term that applies to ovarian and fallopian tube carcinoma and indicates that the tumor is limited to ovaries (one or both) or fallopian tube(s) or the tumor involves one or both ovaries or fallopian tubes with pelvic extension below pelvic brim. There are positive retroperitoneal lymph nodes only (histologically confirmed) and no distant metastasis. (adapted from AJCC 8th Ed.)	Stage IIIA1 | ajcc_pathologic_stage	C177556	ajcc_pathologic_stage
A	C177537	GDC Value Terminology	C139981	Stage IIIA2	A stage term that applies to ovarian and fallopian tube carcinoma and indicates the presence of microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. There is no distant metastasis. (adapted from AJCC 8th Ed.)	Stage IIIA2 | ajcc_pathologic_stage	C177556	ajcc_pathologic_stage
C	C177537	GDC Value Terminology	C141478	Not Allowed To Collect	An indicator that specifies that a collection event was not permitted.	Not Allowed To Collect | biospecimen_anatomic_site || Not Allowed To Collect | classification_of_tumor || Not Allowed To Collect | last_known_disease_status || Not Allowed To Collect | method_of_sample_procurement || Not Allowed To Collect | normal_tumor_genotype_snp_match || Not Allowed To Collect | prior_malignancy || Not Allowed To Collect | prior_treatment || Not Allowed To Collect | progression_or_recurrence || Not Allowed To Collect | sample_type || Not Allowed To Collect | vascular_invasion_present || Not Allowed To Collect | vital_status || not allowed to collect | ethnicity || not allowed to collect | race || not allowed to collect | vital_status	C127772 || C16124 || C16564 || C17049 || C171435 || C174459 || C177599 || C177601 || C177617 || C18849 || C25717 || C70700 || C70713	vascular_invasion_present || prior_treatment || ethnicity || race || biospecimen_anatomic_site || classification_of_tumor || normal_tumor_genotype_snp_match || progression_or_recurrence || last_known_disease_status || history_of_tumor || prior_malignancy || vital_status || method_of_sample_procurement || sample_type
D	C177537	GDC Value Terminology	C14219	Human Immunodeficiency Virus	The virus isolated and recognized as the etiologic agent of AIDS. HIV-1 is classified as a lentivirus, a subtype of retroviruses.	HIV | risk_factor	C17103	risk_factor
C	C177537	GDC Value Terminology	C153314	Guretolimod	A synthetic, small molecule, toll-like receptor (TLR) 7 agonist, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, guretolimod activates TLR7, resulting in type I interferon secretion and activation of  cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.	Toll-like Receptor 7 Agonist DSP-0509 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C156061	Mupadolimab	A type II humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, mupadolimab targets and binds to CD73 on tumor cells, leading to internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.	Anti-CD73 Monoclonal Antibody CPI-006 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C157431	Red and Violet	The combination of red and violet colors.	Red & Violet | eye_color	C157437	eye_color
A	C177537	GDC Value Terminology	C160244	Other Eye Color	The color of the eye was identified in the study but is not present in the form.	Other | eye_color	C157437	eye_color
A	C177537	GDC Value Terminology	C175520	Dairy or Lactose Intolerance Allergy	An allergic reaction triggered by exposure to allergens found in foods containing lactose or other dairy components.	Allergy, Dairy or Lactose | risk_factor	C17103	risk_factor
A	C177537	GDC Value Terminology	C175521	Nut Allergy	An allergic reaction triggered by exposure to allergens found in nuts.	Allergy, Nuts | risk_factor	C17103	risk_factor
A	C177537	GDC Value Terminology	C175522	Processed Food Allergy	An allergic reaction triggered by exposure to allergens found in processed foods.	Allergy, Processed Foods | risk_factor	C17103	risk_factor
C	C177537	GDC Value Terminology	C17666	Germline Variation	Any mutation that appears in the gametes and which will therefore be transmitted to the progeny with some frequency.	Germline | variant_origin	C177604	variant_origin
A	C177537	GDC Value Terminology	C178422	Talc Poudrage	A surgical procedure in which talc is insufflated into the pleural space during thoracoscopy to promote the adhesion of the visceral and parietal layers of the pleura as a treatment for recurring pleural effusion.	Pleurodesis, Talc | additional_pathology_findings	C158809	additional_pathology_findings
C	C177537	GDC Value Terminology	C17998	Unknown	Not known, observed, recorded; or reported as unknown by the data contributor.	Unknown | ajcc_clinical_m || Unknown | ajcc_clinical_n || Unknown | ajcc_clinical_stage || Unknown | ajcc_clinical_t || Unknown | ajcc_pathologic_m || Unknown | ajcc_pathologic_n || Unknown | ajcc_pathologic_stage || Unknown | ajcc_pathologic_t || Unknown | ajcc_staging_system_edition || Unknown | alcohol_history || Unknown | alcohol_intensity || Unknown | alcohol_type || Unknown | anaplasia_present || Unknown | anaplasia_present_type || Unknown | ann_arbor_b_symptoms || Unknown | ann_arbor_clinical_stage || Unknown | ann_arbor_extranodal_involvement || Unknown | ann_arbor_pathologic_stage || Unknown | antigen || Unknown | asbestos_exposure || Unknown | barretts_esophagus_goblet_cells_present || Unknown | biospecimen_anatomic_site || Unknown | biospecimen_laterality || Unknown | biospecimen_type || Unknown | bone_marrow_malignant_cells || Unknown | burkitt_lymphoma_clinical_variant || Unknown | cause_of_death || Unknown | cause_of_death_source || Unknown | cdc_hiv_risk_factors || Unknown | chemo_concurrent_to_radiation || Unknown | child_pugh_classification || Unknown | chipseq_antibody || Unknown | chipseq_target || Unknown | chromosome || Unknown | classification_of_tumor || Unknown | coal_dust_exposure || Unknown | cog_liver_stage || Unknown | cog_neuroblastoma_risk_group || Unknown | cog_renal_stage || Unknown | cog_rhabdomyosarcoma_risk_group || Unknown | columnar_mucosa_present || Unknown | comorbidity || Unknown | comorbidity_method_of_diagnosis || Unknown | composition || Unknown | diabetes_treatment_type || Unknown | diagnosis_pathologically_confirmed || Unknown | disease_response || Unknown | disease_type || Unknown | distance_normal_to_tumor || Unknown | dysplasia_degree || Unknown | dysplasia_type || Unknown | ecog_performance_status || Unknown | eln_risk_classification || Unknown | enneking_msts_grade || Unknown | enneking_msts_metastasis || Unknown | enneking_msts_stage || Unknown | enneking_msts_tumor_site || Unknown | environmental_tobacco_smoke_exposure || Unknown | esophageal_columnar_dysplasia_degree || Unknown | esophageal_columnar_metaplasia_present || Unknown | ethnicity || Unknown | exposure_duration || Unknown | figo_stage || Unknown | first_symptom_prior_to_diagnosis || Unknown | fragmentation_enzyme || Unknown | gastric_esophageal_junction_involvement || Unknown | gene_symbol || Unknown | goblet_cells_columnar_mucosa_present || Unknown | haart_treatment_indicator || Unknown | hepatitis_sustained_virological_response || Unknown | histone_family || Unknown | histone_variant || Unknown | hormonal_contraceptive_type || Unknown | hormonal_contraceptive_use || Unknown | hormone_replacement_therapy_type || Unknown | hpv_positive_type || Unknown | hysterectomy_margins_involved || Unknown | hysterectomy_type || Unknown | igcccg_stage || Unknown | imaging_result || Unknown | immunosuppressive_treatment_type || Unknown | initial_disease_status || Unknown | inpc_grade || Unknown | inpc_histologic_group || Unknown | inrg_stage || Unknown | inss_stage || Unknown | instrument_model || Unknown | irs_group || Unknown | irs_stage || Unknown | ishak_fibrosis_score || Unknown | iss_stage || Unknown | karnofsky_performance_status || Unknown | laboratory_test || Unknown | largest_extrapelvic_peritoneal_focus || Unknown | laterality || Unknown | lost_to_followup || Unknown | lymph_node_involved_site || Unknown | lymph_node_involvement || Unknown | lymphatic_invasion_present || Unknown | margin_status || Unknown | medulloblastoma_molecular_classification || Unknown | menopause_status || Unknown | metaplasia_present || Unknown | metastasis_at_diagnosis || Unknown | metastasis_at_diagnosis_site || Unknown | method_of_diagnosis || Unknown | method_of_sample_procurement || Unknown | micropapillary_features || Unknown | mismatch_repair_mutation || Unknown | mitosis_karyorrhexis_index || Unknown | molecular_analysis_method || Unknown | morphology || Unknown | non_nodal_regional_disease || Unknown | non_nodal_tumor_deposits || Unknown | normal_tumor_genotype_snp_match || Unknown | ovarian_specimen_status || Unknown | ovarian_surface_involvement || Unknown | perineural_invasion_present || Unknown | peripancreatic_lymph_nodes_positive || Unknown | peritoneal_fluid_cytological_status || Unknown | ploidy || Unknown | pregnancy_outcome || Unknown | pregnant_at_diagnosis || Unknown | premature_at_birth || Unknown | preservation_method || Unknown | primary_diagnosis || Unknown | primary_site || Unknown | prior_treatment || Unknown | procedures_performed || Unknown | progression_or_recurrence || Unknown | progression_or_recurrence_anatomic_site || Unknown | progression_or_recurrence_type || Unknown | race || Unknown | radon_exposure || Unknown | reflux_treatment_type || Unknown | relationship_primary_diagnosis || Unknown | relationship_type || Unknown | residual_disease || Unknown | respirable_crystalline_silica_exposure || Unknown | risk_factor || Unknown | risk_factor_treatment || Unknown | sample_type || Unknown | satellite_nodule_present || Unknown | second_gene_symbol || Unknown | secondhand_smoke_as_child || Unknown | site_of_resection_or_biopsy || Unknown | smoking_frequency || Unknown | supratentorial_localization || Unknown | synchronous_malignancy || Unknown | target_capture_kit || Unknown | test_analyte_type || Unknown | test_result || Unknown | therapeutic_agents || Unknown | time_between_waking_and_first_smoke || Unknown | tissue_or_organ_of_origin || Unknown | tissue_type || Unknown | tobacco_smoking_status || Unknown | transglottic_extension || Unknown | treatment_anatomic_site || Unknown | treatment_effect || Unknown | treatment_effect_indicator || Unknown | treatment_frequency || Unknown | treatment_intent_type || Unknown | treatment_outcome || Unknown | treatment_type || Unknown | tumor_confined_to_organ_of_origin || Unknown | tumor_descriptor || Unknown | tumor_focality || Unknown | tumor_grade || Unknown | tumor_regression_grade || Unknown | type_of_smoke_exposure || Unknown | variant_origin || Unknown | variant_type || Unknown | vascular_invasion_present || Unknown | vascular_invasion_type || Unknown | viral_hepatitis_serologies || Unknown | vital_status || Unknown | who_cns_grade || Unknown | who_nte_grade || Unknown | wilms_tumor_histologic_subtype || Unknown | zygosity || unknown | gender || unknown | prior_malignancy || unknown | progression_or_recurrence || unknown | relationship_gender || unknown | relative_with_cancer_history || unknown | treatment_or_therapy || unknown | vital_status	C102562 || C105721 || C106304 || C106317 || C106541 || C111073 || C112400 || C121007 || C123560 || C125738 || C126378 || C127768 || C127772 || C129439 || C13202 || C133427 || C133706 || C139007 || C140258 || C140259 || C140262 || C140266 || C141342 || C15256 || C15599 || C156421 || C156422 || C157110 || C157233 || C157410 || C157425 || C158874 || C159824 || C160720 || C160827 || C160996 || C16124 || C161320 || C16165 || C162221 || C164057 || C16457 || C16515 || C16564 || C166229 || C16687 || C17001 || C17049 || C17103 || C171253 || C17140 || C171435 || C173544 || C17357 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177570 || C177571 || C177572 || C177573 || C177574 || C177575 || C177576 || C177578 || C177583 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177597 || C177598 || C177599 || C177600 || C177601 || C177603 || C177604 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177613 || C177614 || C177616 || C177619 || C177620 || C177621 || C177622 || C177624 || C177625 || C177626 || C177627 || C177628 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C18849 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C25185 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C29878 || C2991 || C33027 || C35529 || C36037 || C36292 || C38032 || C4086 || C43568 || C45824 || C45902 || C4809 || C49236 || C50995 || C53414 || C54398 || C55816 || C574 || C70700 || C70713 || C70729 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C95149 || C99532	inpc_grade || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || alcohol_intensity || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || inrg_stage || mismatch_repair_mutation || iss_stage || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || hysterectomy_type || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || hpv_positive_type || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || primary_site || lost_to_followup || lymphatic_invasion_present || satellite_nodule_present || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || type_of_smoke_exposure || comorbidity || fragmentation_enzyme || ethnicity || tumor_descriptor || histone_family || ploidy || race || risk_factor || second_gene_symbol || environmental_tobacco_smoke_exposure || biospecimen_anatomic_site || variant_type || gender || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || radon_exposure || coal_dust_exposure || respirable_crystalline_silica_exposure || method_of_diagnosis || dysplasia_degree || target_capture_kit || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || risk_factor_treatment || variant_origin || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serologies || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || chipseq_antibody || chipseq_target || initial_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || metastasis_at_diagnosis_site || secondhand_smoke_as_child || smoking_frequency || time_between_waking_and_first_smoke || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || history_of_tumor || prior_malignancy || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || laterality || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || relative_with_cancer_history || disease_type || lymph_node_involved_site || lymph_node_involvement || tumor_confined_to_organ_of_origin || test_result || treatment_effect || dysplasia_type || gene_symbol || zygosity || alcohol_type || residual_disease || treatment_or_therapy || disease_response || composition || treatment_intent_type || asbestos_exposure || immunosuppressive_treatment_type || method_of_sample_procurement || sample_type || treatment_anatomic_site || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || ishak_fibrosis_score || diabetes_treatment_type
C	C177537	GDC Value Terminology	C18060	Somatic Variation	Any mutation with an origin in cells that are not destined to become gametes. As a consequence, such mutations are not transmitted to progeny, though they will be transmitted during any mitosis within the individual. Somatic mutations may contribute to a broad variety of pathologies including cancer.	Somatic | variant_origin	C177604	variant_origin
C	C177537	GDC Value Terminology	C25228	Right	Being or located on or directed toward the side of the body to the east when facing north.	Right | biospecimen_laterality || Right | laterality || Right | undescended_testis_corrected_laterality	C177605 || C181723 || C25185	biospecimen_laterality || undescended_testis_corrected_laterality || laterality
C	C177537	GDC Value Terminology	C25229	Left	Being or located on or directed toward the side of the body to the west when facing north.	Left | biospecimen_laterality || Left | laterality || Left | undescended_testis_corrected_laterality	C177605 || C181723 || C25185	biospecimen_laterality || undescended_testis_corrected_laterality || laterality
A	C177537	GDC Value Terminology	C26744	Dermatomyositis	Inflammation of the skin and muscle.	Dermatomyosis | comorbidity || Dermatomyosis | risk_factor	C16457 || C17103	comorbidity || risk_factor
C	C177537	GDC Value Terminology	C28052	Stage IB1	A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b1, N0, M0. (partially adapted from AJCC)	Stage IB1 | ajcc_clinical_stage || Stage IB1 | ajcc_pathologic_stage	C177555 || C177556	ajcc_clinical_stage || ajcc_pathologic_stage
C	C177537	GDC Value Terminology	C28053	Stage IB2	A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b2, N0, M0.  (partially adapted from AJCC)	Stage IB2 | ajcc_clinical_stage || Stage IB2 | ajcc_pathologic_stage	C177555 || C177556	ajcc_clinical_stage || ajcc_pathologic_stage
A	C177537	GDC Value Terminology	C3108	HIV Infection	An infection caused by the human immunodeficiency virus.	HIV | risk_factor	C17103	risk_factor
A	C177537	GDC Value Terminology	C38267	Intrathecal Route of Administration	Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.	Intrathecal Route of Administration | route_of_administration	C38114	route_of_administration
A	C177537	GDC Value Terminology	C38276	Intravenous Route of Administration	Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.	Intravenous Route of Administration | route_of_administration	C38114	route_of_administration
A	C177537	GDC Value Terminology	C38288	Oral Route of Administration	The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.	Oral | route_of_administration	C38114	route_of_administration
C	C177537	GDC Value Terminology	C40079	Ovarian Clear Cell Adenocarcinofibroma	A malignant neoplasm of the ovary with an invasive epithelial component and a fibrotic stroma. The epithelial component is characterized by the presence of malignant epithelial cells with clear cytoplasm.	8313/3 | morphology || Clear cell adenocarcinofibroma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C43234	Not Reported	Not provided or available.	Not Reported | ajcc_clinical_m || Not Reported | ajcc_clinical_n || Not Reported | ajcc_clinical_stage || Not Reported | ajcc_clinical_t || Not Reported | ajcc_pathologic_m || Not Reported | ajcc_pathologic_n || Not Reported | ajcc_pathologic_stage || Not Reported | ajcc_pathologic_t || Not Reported | ajcc_staging_system_edition || Not Reported | alcohol_history || Not Reported | alcohol_intensity || Not Reported | alcohol_type || Not Reported | anaplasia_present || Not Reported | anaplasia_present_type || Not Reported | ann_arbor_b_symptoms || Not Reported | ann_arbor_clinical_stage || Not Reported | ann_arbor_extranodal_involvement || Not Reported | ann_arbor_pathologic_stage || Not Reported | antigen || Not Reported | asbestos_exposure || Not Reported | barretts_esophagus_goblet_cells_present || Not Reported | biospecimen_anatomic_site || Not Reported | biospecimen_laterality || Not Reported | biospecimen_type || Not Reported | bone_marrow_malignant_cells || Not Reported | burkitt_lymphoma_clinical_variant || Not Reported | cause_of_death || Not Reported | cause_of_death_source || Not Reported | cdc_hiv_risk_factors || Not Reported | chemo_concurrent_to_radiation || Not Reported | child_pugh_classification || Not Reported | chromosome || Not Reported | cog_liver_stage || Not Reported | cog_neuroblastoma_risk_group || Not Reported | cog_renal_stage || Not Reported | cog_rhabdomyosarcoma_risk_group || Not Reported | columnar_mucosa_present || Not Reported | comorbidity || Not Reported | comorbidity_method_of_diagnosis || Not Reported | composition || Not Reported | consistent_pathology_review || Not Reported | diabetes_treatment_type || Not Reported | diagnosis_pathologically_confirmed || Not Reported | disease_response || Not Reported | disease_type || Not Reported | distance_normal_to_tumor || Not Reported | dysplasia_degree || Not Reported | dysplasia_type || Not Reported | ecog_performance_status || Not Reported | eln_risk_classification || Not Reported | enneking_msts_grade || Not Reported | enneking_msts_metastasis || Not Reported | enneking_msts_stage || Not Reported | enneking_msts_tumor_site || Not Reported | esophageal_columnar_dysplasia_degree || Not Reported | esophageal_columnar_metaplasia_present || Not Reported | exposure_duration || Not Reported | eye_color || Not Reported | figo_stage || Not Reported | first_symptom_prior_to_diagnosis || Not Reported | gastric_esophageal_junction_involvement || Not Reported | gene_symbol || Not Reported | gleason_grade_group || Not Reported | goblet_cells_columnar_mucosa_present || Not Reported | haart_treatment_indicator || Not Reported | hepatitis_sustained_virological_response || Not Reported | histone_family || Not Reported | histone_variant || Not Reported | hormonal_contraceptive_type || Not Reported | hormonal_contraceptive_use || Not Reported | hormone_replacement_therapy_type || Not Reported | hpv_positive_type || Not Reported | hysterectomy_margins_involved || Not Reported | hysterectomy_type || Not Reported | igcccg_stage || Not Reported | imaging_result || Not Reported | immunosuppressive_treatment_type || Not Reported | initial_disease_status || Not Reported | inpc_grade || Not Reported | inpc_histologic_group || Not Reported | inrg_stage || Not Reported | inss_stage || Not Reported | instrument_model || Not Reported | irs_group || Not Reported | irs_stage || Not Reported | ishak_fibrosis_score || Not Reported | iss_stage || Not Reported | karnofsky_performance_status || Not Reported | laboratory_test || Not Reported | largest_extrapelvic_peritoneal_focus || Not Reported | laterality || Not Reported | lymph_node_involved_site || Not Reported | lymph_node_involvement || Not Reported | lymphatic_invasion_present || Not Reported | margin_status || Not Reported | medulloblastoma_molecular_classification || Not Reported | menopause_status || Not Reported | metaplasia_present || Not Reported | metastasis_at_diagnosis || Not Reported | metastasis_at_diagnosis_site || Not Reported | method_of_diagnosis || Not Reported | method_of_sample_procurement || Not Reported | micropapillary_features || Not Reported | mismatch_repair_mutation || Not Reported | mitosis_karyorrhexis_index || Not Reported | molecular_analysis_method || Not Reported | morphology || Not Reported | necrosis_present || Not Reported | non_nodal_regional_disease || Not Reported | non_nodal_tumor_deposits || Not Reported | normal_tumor_genotype_snp_match || Not Reported | ovarian_specimen_status || Not Reported | ovarian_surface_involvement || Not Reported | perineural_invasion_present || Not Reported | peripancreatic_lymph_nodes_positive || Not Reported | peritoneal_fluid_cytological_status || Not Reported | ploidy || Not Reported | pregnancy_outcome || Not Reported | pregnant_at_diagnosis || Not Reported | premature_at_birth || Not Reported | preservation_method || Not Reported | primary_diagnosis || Not Reported | primary_site || Not Reported | prior_treatment || Not Reported | procedures_performed || Not Reported | progression_or_recurrence || Not Reported | progression_or_recurrence_anatomic_site || Not Reported | progression_or_recurrence_type || Not Reported | radon_exposure || Not Reported | reflux_treatment_type || Not Reported | relationship_primary_diagnosis || Not Reported | relationship_type || Not Reported | residual_disease || Not Reported | rhabdoid_present || Not Reported | risk_factor || Not Reported | risk_factor_treatment || Not Reported | route_of_administration || Not Reported | sample_type || Not Reported | sarcomatoid_present || Not Reported | satellite_nodule_present || Not Reported | second_gene_symbol || Not Reported | secondhand_smoke_as_child || Not Reported | site_of_resection_or_biopsy || Not Reported | supratentorial_localization || Not Reported | synchronous_malignancy || Not Reported | test_analyte_type || Not Reported | test_result || Not Reported | therapeutic_agents || Not Reported | tissue_or_organ_of_origin || Not Reported | tissue_type || Not Reported | tobacco_smoking_status || Not Reported | transglottic_extension || Not Reported | treatment_anatomic_site || Not Reported | treatment_effect || Not Reported | treatment_effect_indicator || Not Reported | treatment_frequency || Not Reported | treatment_intent_type || Not Reported | treatment_outcome || Not Reported | treatment_type || Not Reported | tumor_confined_to_organ_of_origin || Not Reported | tumor_descriptor || Not Reported | tumor_focality || Not Reported | tumor_grade || Not Reported | tumor_regression_grade || Not Reported | undescended_testis_corrected_laterality || Not Reported | variant_type || Not Reported | vascular_invasion_present || Not Reported | vascular_invasion_type || Not Reported | viral_hepatitis_serologies || Not Reported | vital_status || Not Reported | who_cns_grade || Not Reported | who_nte_grade || Not Reported | wilms_tumor_histologic_subtype || Not Reported | zygosity || not reported | classification_of_tumor || not reported | ethnicity || not reported | gender || not reported | last_known_disease_status || not reported | prior_malignancy || not reported | progression_or_recurrence || not reported | race || not reported | relationship_gender || not reported | relative_with_cancer_history || not reported | treatment_or_therapy || not reported | vital_status	C102562 || C105721 || C106304 || C106317 || C106541 || C111073 || C112400 || C121007 || C123560 || C125738 || C126378 || C127768 || C127772 || C129439 || C13202 || C133427 || C133706 || C139007 || C140258 || C140259 || C140262 || C140266 || C141342 || C142346 || C15256 || C15599 || C156421 || C156422 || C157110 || C157233 || C157410 || C157425 || C157437 || C158874 || C160720 || C160827 || C160996 || C16124 || C161320 || C16165 || C162221 || C16457 || C16564 || C166229 || C16687 || C17001 || C17049 || C17103 || C171253 || C171435 || C173544 || C17357 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177570 || C177571 || C177572 || C177573 || C177576 || C177578 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177596 || C177597 || C177598 || C177599 || C177600 || C177601 || C177602 || C177603 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177616 || C177617 || C177619 || C177620 || C177621 || C177622 || C177624 || C177625 || C177626 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C181720 || C181723 || C18849 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C25185 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C29878 || C2991 || C33027 || C35529 || C36037 || C36292 || C38032 || C38114 || C39694 || C4086 || C43568 || C45824 || C45902 || C4809 || C49236 || C50995 || C53414 || C54398 || C55816 || C574 || C70700 || C70713 || C70729 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C95149 || C99532	inpc_grade || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || alcohol_intensity || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || inrg_stage || mismatch_repair_mutation || iss_stage || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || gleason_grade_group || hysterectomy_type || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || hpv_positive_type || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || eye_color || primary_site || lymphatic_invasion_present || satellite_nodule_present || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || comorbidity || ethnicity || tumor_descriptor || histone_family || ploidy || race || risk_factor || second_gene_symbol || biospecimen_anatomic_site || variant_type || gender || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || radon_exposure || method_of_diagnosis || dysplasia_degree || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || necrosis_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serologies || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || initial_disease_status || last_known_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || metastasis_at_diagnosis_site || secondhand_smoke_as_child || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || consistent_pathology_review || undescended_testis_corrected_laterality || history_of_tumor || prior_malignancy || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || laterality || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || relative_with_cancer_history || disease_type || lymph_node_involved_site || lymph_node_involvement || tumor_confined_to_organ_of_origin || test_result || treatment_effect || route_of_administration || sarcomatoid_present || dysplasia_type || gene_symbol || zygosity || alcohol_type || residual_disease || treatment_or_therapy || disease_response || composition || treatment_intent_type || asbestos_exposure || immunosuppressive_treatment_type || method_of_sample_procurement || sample_type || treatment_anatomic_site || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || ishak_fibrosis_score || diabetes_treatment_type
C	C177537	GDC Value Terminology	C4474	Chondroid Syringoma	A rare, benign, slow-growing and painless neoplasm of sweat glands. It usually arises in the head and neck. It is characterized by the presence of a mesenchymal chondroid stroma, fibrosis, and epithelial structures.	8940/0 | morphology || Chondroid syringoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C48324	Gray	An achromatic color of any lightness between the extremes of black and white.	Gray | eye_color	C157437	eye_color
A	C177537	GDC Value Terminology	C48329	Green	The hue of that portion of the visible spectrum lying between yellow and blue, evoked in the human observer by radiant energy with wavelengths of approximately 490 to 570 nanometers; any of a group of colors that may vary in lightness and saturation and whose hue is that of the emerald or somewhat less yellow than that of growing grass.	Green | eye_color	C157437	eye_color
A	C177537	GDC Value Terminology	C48332	Brown	Any of a group of colors between red and yellow in hue that are medium to low in lightness and low to moderate in saturation.	Brown | eye_color	C157437	eye_color
A	C177537	GDC Value Terminology	C48333	Blue	The hue of that portion of the visible spectrum lying between green and indigo, evoked in the human observer by radiant energy with wavelengths of approximately 420 to 490 nanometers; any of a group of colors that may vary in lightness and saturation, whose hue is that of a clear daytime sky.	Blue | eye_color	C157437	eye_color
C	C177537	GDC Value Terminology	C49487	No	The non-affirmative response to a question.	No | alcohol_history || No | anaplasia_present || No | ann_arbor_b_symptoms || No | ann_arbor_extranodal_involvement || No | asbestos_exposure || No | barretts_esophagus_goblet_cells_present || No | bone_marrow_malignant_cells || No | chemo_concurrent_to_radiation || No | coal_dust_exposure || No | columnar_mucosa_present || No | consistent_pathology_review || No | diagnosis_pathologically_confirmed || No | environmental_tobacco_smoke_exposure || No | esophageal_columnar_metaplasia_present || No | gastric_esophageal_junction_involvement || No | goblet_cells_columnar_mucosa_present || No | haart_treatment_indicator || No | hepatitis_sustained_virological_response || No | lost_to_followup || No | lymphatic_invasion_present || No | metaplasia_present || No | mismatch_repair_mutation || No | necrosis_present || No | non_nodal_tumor_deposits || No | normal_tumor_genotype_snp_match || No | perineural_invasion_present || No | pregnant_at_diagnosis || No | premature_at_birth || No | prior_treatment || No | progression_or_recurrence || No | radon_exposure || No | respirable_crystalline_silica_exposure || No | rhabdoid_present || No | risk_factor_treatment || No | sarcomatoid_present || No | secondhand_smoke_as_child || No | synchronous_malignancy || No | treatment_effect_indicator || No | tumor_confined_to_organ_of_origin || No | vascular_invasion_present || no | prior_malignancy || no | progression_or_recurrence || no | relative_with_cancer_history || no | treatment_or_therapy	C112400 || C127768 || C127772 || C133706 || C141342 || C159824 || C160720 || C16124 || C161320 || C16165 || C17140 || C177573 || C177574 || C177575 || C177585 || C177586 || C177587 || C177589 || C177590 || C177591 || C177592 || C177593 || C177595 || C177596 || C177598 || C177599 || C177601 || C177602 || C177603 || C177619 || C177626 || C177634 || C177638 || C178286 || C181720 || C18849 || C29878 || C36037 || C39694 || C49236 || C55816 || C81229	premature_at_birth || perineural_invasion_present || vascular_invasion_present || mismatch_repair_mutation || chemo_concurrent_to_radiation || lost_to_followup || lymphatic_invasion_present || prior_treatment || synchronous_malignancy || haart_treatment_indicator || environmental_tobacco_smoke_exposure || radon_exposure || coal_dust_exposure || respirable_crystalline_silica_exposure || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || metaplasia_present || necrosis_present || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || pregnant_at_diagnosis || secondhand_smoke_as_child || hepatitis_sustained_virological_response || treatment_effect_indicator || anaplasia_present || consistent_pathology_review || history_of_tumor || prior_malignancy || relative_with_cancer_history || tumor_confined_to_organ_of_origin || sarcomatoid_present || treatment_or_therapy || asbestos_exposure || alcohol_history
C	C177537	GDC Value Terminology	C49488	Yes	The affirmative response to a question.	Yes | alcohol_history || Yes | anaplasia_present || Yes | ann_arbor_b_symptoms || Yes | ann_arbor_extranodal_involvement || Yes | asbestos_exposure || Yes | barretts_esophagus_goblet_cells_present || Yes | bone_marrow_malignant_cells || Yes | chemo_concurrent_to_radiation || Yes | coal_dust_exposure || Yes | columnar_mucosa_present || Yes | consistent_pathology_review || Yes | diagnosis_pathologically_confirmed || Yes | environmental_tobacco_smoke_exposure || Yes | esophageal_columnar_metaplasia_present || Yes | gastric_esophageal_junction_involvement || Yes | goblet_cells_columnar_mucosa_present || Yes | haart_treatment_indicator || Yes | hepatitis_sustained_virological_response || Yes | lost_to_followup || Yes | lymphatic_invasion_present || Yes | metaplasia_present || Yes | mismatch_repair_mutation || Yes | necrosis_present || Yes | non_nodal_tumor_deposits || Yes | normal_tumor_genotype_snp_match || Yes | perineural_invasion_present || Yes | pregnant_at_diagnosis || Yes | premature_at_birth || Yes | prior_treatment || Yes | progression_or_recurrence || Yes | radon_exposure || Yes | respirable_crystalline_silica_exposure || Yes | rhabdoid_present || Yes | risk_factor_treatment || Yes | sarcomatoid_present || Yes | secondhand_smoke_as_child || Yes | synchronous_malignancy || Yes | treatment_effect_indicator || Yes | tumor_confined_to_organ_of_origin || Yes | vascular_invasion_present || yes | prior_malignancy || yes | progression_or_recurrence || yes | relative_with_cancer_history || yes | treatment_or_therapy	C112400 || C127768 || C127772 || C133706 || C141342 || C159824 || C160720 || C16124 || C161320 || C16165 || C17140 || C177573 || C177574 || C177575 || C177585 || C177586 || C177587 || C177589 || C177590 || C177591 || C177592 || C177593 || C177595 || C177596 || C177598 || C177599 || C177601 || C177602 || C177603 || C177619 || C177626 || C177634 || C177638 || C178286 || C181720 || C18849 || C29878 || C36037 || C39694 || C49236 || C55816 || C81229	premature_at_birth || perineural_invasion_present || vascular_invasion_present || mismatch_repair_mutation || chemo_concurrent_to_radiation || lost_to_followup || lymphatic_invasion_present || prior_treatment || synchronous_malignancy || haart_treatment_indicator || environmental_tobacco_smoke_exposure || radon_exposure || coal_dust_exposure || respirable_crystalline_silica_exposure || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || metaplasia_present || necrosis_present || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || pregnant_at_diagnosis || secondhand_smoke_as_child || hepatitis_sustained_virological_response || treatment_effect_indicator || anaplasia_present || consistent_pathology_review || history_of_tumor || prior_malignancy || relative_with_cancer_history || tumor_confined_to_organ_of_origin || sarcomatoid_present || treatment_or_therapy || asbestos_exposure || alcohol_history
C	C177537	GDC Value Terminology	C66899	Pleurodesis	A therapeutic surgical procedure in which the pleural space is surgically eliminated by the adherence of the visceral and parietal pleurae.	Pleurodesis | treatment_type || Pleurodesis, NOS | additional_pathology_findings	C158809 || C25218	additional_pathology_findings || treatment_type
C	C177537	GDC Value Terminology	C71079	Herpes Zoster	A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposure to the virus in the form of varicella (chickenpox). It is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area.	Herpes Zoster | comorbidity || Herpes Zoster | risk_factor || Shingles | comorbidity || Shingles | risk_factor	C16457 || C17103	comorbidity || risk_factor
C	C177537	GDC Value Terminology	C85475	Zolbetuximab	A chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, zolbetuximab specifically targets and binds to CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Zolbetuximab | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C96407	Varicella Zoster Infection	A highly contagious viral infection caused by the varicella zoster virus. Clinically, it may be manifested as shingles or chicken pox.	Varicella Zoster Infection | comorbidity || Varicella Zoster Infection | risk_factor	C16457 || C17103	comorbidity || risk_factor